A new 100 mg tablet formulation of ritonavir has been developed that would not require refrigeration. This study compared the single-dose bioavailability of the final ritonavir 100 mg tablet formulation following a moderate-fat or high-fat meal relative to that under fasting conditions.
MethodsThis was a single-dose, open-label, 3-period crossover study with a randomized, crossover design. Healthy male and female subjects (n = 27) participated in the study. Serial blood samples were collected for 36 hours after each dose. Ritonavir AUC from time 0 to the last measurable concentration (AUCt) and from time 0 to infinity (AUCinf), maximum plasma concentration (Cmax), and time of Cmax (Tmax) were determined using noncompartmental methods. The bioavailability of the tablet following a meal relative to the fasting condition was assessed by the two one-sided tests procedure using 90% confidence intervals (CI). Safety was assessed throughout the study. Table 1 presents the food effect results of the ritonavir pharmacokinetic parameters following administration of the ritonavir tablet.
Summary of resultsRitonavir Cmax and AUC were approximately 20-24% lower when dosed following a meal compared to administration under fasting conditions. The slight difference in Tmax is consistent with delayed gastric emptying following a meal. Overall, the tablet formulation was generally safe and well tolerated.
ConclusionOverall, ritonavir pharmacokinetics after administration of the tablet are slightly affected by meal content (with moderate or high fat).
Study M05-730 was conducted to compare the safety, tolerability, pharmacokinetics (PK) and antiviral activity for once-daily (QD) and twice-daily (BID) lopinavir/ritonavir (LPV/r) tablet in antiretroviral-naïve subjects. The LPV/ r QD regimen was shown to be non-inferior to the BID regimen. This analysis explores the population PK and pharmacodynamics (PD) of the LPV/r tablets in HIVinfected subjects.
IdentityOther names: BRCC4; BRCC45 HGNC (Hugo): BRE Location: 2p23.2 Local order: According to GeneLoc and NCBI Map Viewer, genes flanking BRE are RBKS 2p23.3 (ribokinase) in the minus strand orientation, and RPL23AP34 2p23.2 (ribosomal protein L23a pseudogene 34) in the positive strand orientation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.